Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

AI Briefing

• – Novo Nordisk's stock has lost over half its value in the past year.
• – The company's recent struggles with diabetes treatment, including a failed trial of a potential new treatment.
• – Investors may see it as a buying opportunity despite the challenges.